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Science does not need to take a position on legalizing
the recreational use of cannabis, this is more a political
issue or a personal choice. Cannabis, as the other drugs
of abuse, produces several detrimental effects on brain
function but differently from alcohol, nicotine, cocaine,
heroin and ecstasy (just to cite the most commune ab-
used ones) these are mostly present with acute intoxic-
ation and disappear after termination of drug intake.
Consequently, there is no scientific reason for which
we have some legal drugs of abuse such as alcohol and
tobacco sold by governments and others labelled as il-
legal and banned by society. This is, of course, a flawed
situation but one that illustrates a major paradox in
international laws on drugs. Despite being illegal, can-
nabis is (ab)used by about 87.6 million European adults
(23.7% of adults) (EMCDDA, 2017). Cannabis is also
the most commonly used illicit drug among the Maltese
adult population aged 18–65 years. According to the
2013 general population study, around 4.3% of those
aged 18–65 years reported having used cannabis during
their lifetime (EMCDDA, 2017).
One of the most controversial issues in science but
also in the media regards the link between marijuana
and schizophrenia. It has been shown that marijuana
significantly increases the risk of developing a psychotic
disorder later in life, particularly among those individu-
als who use it at an early age, who frequently use high-
potency cannabis or ‘skunk’ and who have a genetic pre-
disposition to psychosis (Aas et al., 2018; Evins, Green,
Kane & Murray, 2013). On the other hand, adult-onset
cannabis use may not be associated with the same level
of risk (Donoghue et al., 2014).
The link between smoking marijuana and schizo-
phrenia is much more complicated than we thought, and
as with other scientific issues, we do not have a certain
response. Firstly, the aetiology of schizophrenia is very
complex. In addition, not just cannabis, but also ab-
use of nicotine (cigarettes smoking) (Gurillo, Jauhar,
Murray & MacCabe, 2015), alcohol (Jordaan & Emsley,
2014), hallucinogens, sedatives and other substances has
also been found to significantly increase the risk of de-
veloping schizophrenia (Gururajan, Manning, Klug &
van den Buuse, 2012). Therefore, one potential source
of overestimating this link is neglecting the effect of
a poly-drug abuse when correcting the epidemiological
data analyses. For example, a recent large longitudinal
Danish study on 3,133,968 individuals (Nielsen, Toft-
dahl, Nordentoft & Hjorthoj, 2017) that took into con-
sideration the effect of a poly-drug abuse showed a lower
association compared with previous studies, with can-
nabis and alcohol abuse increases the risk of developing
schizophrenia later in life by five and three times, re-
spectively.
Caution should be taken when using these epidemi-
ological data though since we really do not know if
these findings indicate a causal relationship. Indeed,
they might just simply indicate that those who have a
predisposition to develop schizophrenia later on in life
are more likely to use cannabis and indeed we know
that they are more likely to suffer comorbid substance
use disorders than the general population. If there is a
causal role between cannabis and schizophrenia, recent
results suggest that this may have been overestimated.
The lack of data regarding an increase in schizophrenia
incidence in countries where marijuana is legal tend to
suggest this possible scenario.
Nevertheless, extreme caution has to be taken re-
garding the (ab)use of all drugs of addiction, includ-
ing marijuana. Marijuana should definitely be forbidden
to adolescents. People with a family history of schizo-
phrenia should avoid cannabis but schizophrenia is not
just caused by marijuana. Events that might have the
potential to cause stress can also play a part, because
genes and the environment are interconnected. Thus,
people who are at risk should try to avoid substances
that might damage their mental well-being. These sub-
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stances include marijuana or any other drug of abuse,
including those that can be legally bought at any shops.
Nevertheless, I believe that marijuana and research
on cannabinoids may give rise to the discovery of new
potential treatments for many disorders, especially epi-
lepsy. This idea is also shared by many neuroscientists
including Dr Mechoulam (personal communication, see
Fig. 1) who discovered THC in the ’60s (Mechoulam &
Gaoni, 1965).
Figure 1: Left, Raphael Mechoulam (Hebrew University, Israel),
right, Giuseppe Di Giovanni (University of Malta, Malta) at the
MNS2017 in Malta. On the background on the left, Prof. Giacomo
Rizzolatti (University of Parma, Italy).
Different lines of my research in Malta are focused on
the effect of cannabinoids on different types of neuro-
psychiatric disorders, such as drugs of addiction, anxi-
ety and epilepsy. I do not use the chemical found
in marijuana called delta-9 tetrahydrocannabinol (∆9-
THC), which induces marijuana’s psychotropic effects,
but a synthetic analogue named WIN 55,212-2, that is
many times more powerful than ∆9-THC. As far as focal
epilepsy is concerned, we have found that in temporal
lobe epilepsy, synthetic cannabinoids are even more ef-
fective than the epileptic drug phenytoin. The only
problem with this treatment is that the dose of can-
nabinoid impairs the hippocampus, an important part
of the brain, and thus blocks the process that is needed
for learning and memory. We have bypassed these side
effects by using a new compound that blocks the break-
down of the natural cannabinoids our brain normally
makes the fatty acid amide hydrolase (FAAH) inhib-
itor URB597. The new drug boosts the amount of
self-produced marijuana in epileptics’ brains. The new
compound is less effective in stopping epilepsy but is
longer-lasting without major side effects (Colangeli et
al., 2017). We are currently following this line of inter-
vention, trying other drugs that increase the levels of
our own cannabinoids when and where they are needed
to avoid any possible side effects. This research could
potentially treat millions of epilepsy patients safely.
We are also investigating status epilepticus, a life-
threatening condition in which one epileptic fit follows
the other without the sufferer recovering consciousness.
We found that synthetic cannabinoids only had a mod-
est effect on the development of this type of seizures.
Surprisingly, when serotonin was activated, their effect-
iveness multiplied, stopping the fits. We have discovered
an important interaction between cannabinoids and 5-
HT, at the moment we are investigating various pos-
sibilities and we believe that the outcome could be im-
portant for further understanding of the pathological
mechanisms and for new treatments (unpublished ob-
servations).
Finally, although cannabis has been used for a cen-
tury to treat convulsive and focal epilepsy, no evidence
instead exists of a role for the CB system in human
absence epilepsy, a non-convulsive type of paediatric
epilepsy (Crunelli & Leresche, 2002). Indeed, very few
studies have investigated the involvement of the CB sys-
tem in absence seizures, and their results are highly con-
trasting. Thanks to an RIDT grant I have started to
investigate the role of the eCBs in this type of epilepsy
and the results are very promising.
The governments attitude toward marijuana research
is finally changing. Strikingly, only a few days ago,
on June 25th 2018, the U.S. Food and Drug Admin-
istration today approved Epidiolex (cannabidiol, CBD)
oral solution by GW Research Ltd. for the treatment
of seizures associated with two rare and severe forms
of epilepsy, Lennox-Gastaut syndrome and Dravet syn-
drome, in patients two years of age and older. This
is the first FDA-approved drug that contains a puri-
fied drug substance derived from marijuana. It is also
the first FDA approval of a drug for the treatment
of patients with Dravet syndrome (see FDA News Re-
lease at https://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm611046.htm).
Therefore, marijuana and marijuana research should
not be demonized but encouraged and supported, it may
save millions of lives!
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